Actuate Therapeutics (NASDAQ:ACTU) Releases Quarterly Earnings Results

Actuate Therapeutics (NASDAQ:ACTU) announced its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, FiscalAI reports.

Actuate Therapeutics Stock Performance

Shares of NASDAQ:ACTU traded down $0.05 during mid-day trading on Thursday, hitting $2.27. The stock had a trading volume of 43,030 shares, compared to its average volume of 73,525. The company’s 50 day moving average is $3.98 and its 200-day moving average is $5.82. Actuate Therapeutics has a 12-month low of $2.15 and a 12-month high of $11.99. The company has a market cap of $52.75 million, a PE ratio of -2.61 and a beta of 0.10.

Insiders Place Their Bets

In other Actuate Therapeutics news, Director Todd S. Thomson sold 280,000 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the sale, the director directly owned 904,795 shares of the company’s stock, valued at $5,247,811. The trade was a 23.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 69.34% of the company’s stock.

Institutional Trading of Actuate Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ACTU. ABS Direct Equity Fund LLC acquired a new position in Actuate Therapeutics during the fourth quarter valued at $40,000. Deutsche Bank AG boosted its position in Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after acquiring an additional 8,051 shares during the period. Barclays PLC boosted its position in Actuate Therapeutics by 68.6% during the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock worth $91,000 after acquiring an additional 6,081 shares during the period. Bank of America Corp DE grew its stake in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after acquiring an additional 15,267 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Actuate Therapeutics in the 4th quarter valued at about $102,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ACTU. Wall Street Zen cut Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.